Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial

R S Wallis; P Nsubuga; C Whalen; R D Mugerwa; A Okwera; D Oette; J B Jackson; J L Johnson; J J Ellner

doi:10.1093/infdis/174.4.727

Back

Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial

Journal article

Peer reviewed

Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial

R S Wallis, P Nsubuga, C Whalen, R D Mugerwa, A Okwera, D Oette, J B Jackson, J L Johnson and J J Ellner

The Journal of infectious diseases, Vol.174(4), pp.727-733

10/1996

DOI: 10.1093/infdis/174.4.727

PMID: 8843209

View Online

Abstract

Macrophage activation and tumor necrosis factor-alpha (TNF-alpha) production are critical in tuberculosis immunity but may result in increased human immunodeficiency virus (HIV) expression and accelerated HIV disease progression in HIV-infected persons. Pentoxifylline inhibits expression of TNF-alpha and HIV. A double-blind, placebo-controlled study of adjunctive therapy with pentoxifylline (1800 mg/day) as a timed-release formulation was done in Ugandan HIV-infected patients with pulmonary tuberculosis. Subjects had early HIV disease (mean CD4 cell count, 380/microL) and did not receive other antiretroviral drugs. Pentoxifylline resulted in decreased plasma HIV RNA and serum beta 2-microglobulin and, in a subset of moderately anemic patients, improved blood hemoglobin levels. Trends were noted toward reduced TNF-alpha production in vitro and improved performance scores, but these did not reach statistical significance. No effect was noted on body mass, CD4 cell count, or survival. Additional studies of more potent TNF-alpha inhibitors in HIV-positive subjects with tuberculosis are warranted.

Phosphodiesterase Inhibitors - therapeutic use

Double-Blind Method

HIV Seropositivity - complications

Humans

beta 2-Microglobulin - analysis

Adult

RNA, Viral - blood

Tuberculosis, Pulmonary - drug therapy

Tumor Necrosis Factor-alpha - biosynthesis

Pentoxifylline - adverse effects

Pentoxifylline - therapeutic use

Tuberculosis, Pulmonary - virology

Details

Title: Subtitle: Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial
Creators: R S Wallis - Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4984, USA
P Nsubuga
C Whalen
R D Mugerwa
A Okwera
D Oette
J B Jackson
J L Johnson
J J Ellner
Resource Type: Journal article
Publication Details: The Journal of infectious diseases, Vol.174(4), pp.727-733
DOI: 10.1093/infdis/174.4.727
PMID: 8843209
NLM abbreviation: J Infect Dis
ISSN: 0022-1899
eISSN: 1537-6613
Publisher: United States
Grant note: AI-32414 / NIAID NIH HHS AI-45244 / NIAID NIH HHS
Language: English
Date published: 10/1996
Academic Unit: Pathology; VPMA - Administration
Record Identifier: 9984047602902771

Metrics

14 Record Views

68 Times Cited - Web of Science

See more details